Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood and tissue markers could forecast esophageal cancer return

NCT ID NCT07702253

Knowledge-focused Sponsor: Chinese University of Hong Kong Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 14, 2026 · Last updated Jul 15, 2026 · Updated 1 time

Summary

This study examines whether certain proteins and immune signals in the blood and tumor tissue can predict if esophageal squamous cell carcinoma will come back after treatment. Researchers will collect blood and biopsy samples from 120 adults at diagnosis and during early treatment. By mapping how the immune system interacts with the tumor, they aim to develop a way to identify patients at higher risk of recurrence.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this research could lead to a blood test that helps predict which esophageal cancer patients are at higher risk of recurrence, guiding more personalized treatment decisions.
What could go wrong
This is an observational study, not a treatment trial, so it will not directly improve outcomes. The findings may not translate into a reliable clinical test without further validation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 120 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2026

Expected to finish

Mar 2037

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with histologically confirmed esophageal squamous cell carcinoma receiving care at Prince of Wales Hospital, Hong Kong. Participants will provide tumour tissue and peripheral blood specimens collected during routine diagnostic, treatment, and follow-up procedures.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 years. * Histologically confirmed ESCC * Able to provide written informed consent. * Able to comply with study procedures. Exclusion Criteria: * Withdrawal of consent. * Irreversible coagulation disorders preventing clinically indicated biopsies. * With other co-existing malignancy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Esophageal squamous cell carcinoma (ESCC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Esophageal Neoplasms esophageal squamous cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Esophageal squamous cell carcinoma (ESCC)

Contacts and locations

Locations

  • Department of Surgery, Faculty of Medicine, the Chinese University of Hong Kong

    Hong Kong, Hong Kong

More trials for these conditions

Other studies related to the condition(s) this trial covers.